Sanofi appoints new CMO

10 March 2016

French drugmaker Sanofi (Euronext: SAN) has appointed Ameet Nathwani as its new chief medical officer, it has been announced.

Dr Nathwani, who replaces Paul Chew, will be responsible for enterprise-wide medical, patient safety, medical quality assurance and will ensure the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations, the company said in a statement.

A qualified medic, Dr Nathwani brings more than 20 years’ experience in the pharmaceutical industry to the role. From 1994 he held increasingly senior positions at Glaxo, SmithKline Beecham and GlaxoSmithKline in Europe and the USA, before joining Novartis in 2004 as senior vice president and global development head of the cardiovascular and metabolic franchise.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK